Immunology Review
All Things Thymo
To Reject or Not to Reject
Name that Med
What would you do?
100

This signal involves antigen-presenting cells binding to the T-cell receptor.

What is Signal 1?

100

This is the maximum single dose of thymoglobulin

150 mg

100

Name 3 factors that affect induction agent selection

Younger recipient age, number of HLA mismatches, older donor age, African-American ethnicity, PRA >0%, presence of DSA, blood group incompatibility, delayed graft function, cold ischemia time >24 hours

100

This medication is always given regardless of induction regimen and involves a tapering schedule.

What is methylprednisolone?

100

An endocrinology fellow asked to schedule insulin NPH to be given with the patient's daily steroid dose. Currently the patient is POD1 and has methylprednisolone scheduled at 1300 before their thymoglobulin dose at 1400 on POD1 and POD2, but their prednisone taper starting POD3 is set to be given daily @0900. What would you do?

Do NOT re-time the methylprednisolone to 0900 as they need to be given 1 hour prior to thymoglobulin infusions. Schedule NPH at 0900 daily or can do one time doses at 1300 on POD1 and POD2 the start daily 0900 NPH on POD3.

200

These antibodies are directed specifically against donor antigens and increase rejection risk.

What are donor-specific antibodies (DSA)?

200

What are the two thymoglobulin products that are available and which one do we use for induction at HFH?

Rabbit and horse. We use the rabbit thymoglublin.

200

These kidney transplant recipients should receive no induction

Living Related Donor Transplants that are:

  • 1 or 2 Haplotype match (HM)
  • Non-African American
  • cPRA<20%
200

This medication has immunosuppressant effects that can last anywhere from 6 months to a year and requires frequent monitoring during the infusion.

What is thymoglobulin?

200

A patient is currently POD1 in the SICU post kidney transplant and their induction regimen is 2 dose thymoglobulin via central line. The SICU team wants to remove the central line. What should you recommend?

Change the current central t

300

Expressed as a percentage, this lab test measures the level of sensitizing antibodies in a patient's blood to determine how likely they are to reject a transplant.

 What is Panel Reactive Antibody (or PRA)?

300

These are the pre-meds required for thymoglobulin

Diphenhydramine 50 mg IV, methylprednisolone 250 mg IV, and acetaminophen 650 mg PO given 1 hour before each dose

300

These kidney transplant recipients should receive basiliximab induction

Non-African American patients with cPRA <20% that are:

  • Living Unrelated Donor Transplants
  • Living Related Donor with 0 Haplotype Match
  • Deceased donor with non DCD, KDPI <85%, at low risk of DGF


Non-African American patients with cPRA ≥20% that have:

  • Zero Ag MM with donor
  • History of Extra Renal Transplant
300
This induction agent is a non-depleting chimeric monoclonal antibody against CD25 (IL-2 receptor)

What is basiliximab?

300

A doctor from the OR calls central pharmacy saying they placed a stat order for thymoglobulin for a kidney transplant that is happening now. They ask you to tube the thymoglobulin to tube station 508. What do you do?

Tell them you will make it in the IV room stat and that unfortunately the medication cannot be tubed so please send someone to come to the pharmacy to pick it up.

400

These are the differences between induction and maintenance immunosuppression.

Induction is high-intensity immunosuppression, administered intra-op and immediately post-transplant to prevent rejection when patients are at the highest risk. While maintenance is less intense lifelong immunosuppression to prevent organ rejection long term.

400

If rituximab and thymoglobulin are both indicated for a patient what are the administration considerations?

Rituximab infusion should be administered prior to thymoglobulin if both are indicated. Rituximab and thymoglobulin should NOT be given through the same IV access.

400

These kidney transplant recipients should receive 2 doses of thymoglobulin

Deceased donor transplants who are:

  • Non-African American
  • cPRA <20%
    BUT have a high risk of DGF:
  • DCD
  • KDPI ≥85%
400

This induction agent that depletes both T and B cells is only available through a direct distribution from the manufacturer 

What is alemtuzumab?

400

The transplant team wants to discharge a patient on POD3 because they are stable to go home. They received basiliximab 20 mg IV induction on POD0. What are the next steps?

Administer a second dose of basiliximab 20 mg IV on POD3 before the patient leaves.

500

This cytokine is central to T-cell proliferation and is the downstream target of multiple induction agents.

What is IL-2?

500

How must thymoglobulin be administered peripherally?

Infuse over 12 hours via a large bore peripheral IV (18 g or greater is preferred). A back-up peripheral IV site must be present in the event that the peripheral IV develops phlebitis or infiltrates. Use a 0.22-micron filter.

500

These kidney transplant recipients should receive 3 doses of thymoglobulin

  • All African Americans
  • cPRA>20% (except 0 Ag mismatch Non-African American)
  • Deceased donor with:
    • DCD
    • KDPI ≥85%
    • At risk of DGF
  • Repeat Kidney Transplant
  • Pancreas transplant (SPK, PTA, PAK)
500

This induction agent binds to CD20 to deplete mature B cells by various mechanisms such as mediation of antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and B-cell apoptosis

What is rituximab?

500

A planned A2/A2B kidney transplant is planned and the provider orders Truxima (rituximab-abbs). What are your next steps?

Truxima (rituximab-abbs) is only approved for ambulatory use on our formulary, so ask the provider to change the order to Ruxience (rituximab-pvvr).

M
e
n
u